We will explore the influence of chemotherapy on hair follicles. Scalp cooling works, but not in every patient. When we understand the working mechanism of chemotherapy induced alopecia, we can possibly explain why scalp cooling works in one patient…
ID
Source
Brief title
Condition
- Breast neoplasms benign (incl nipple)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The expression of apoptotic markers in the dystrophic pathway involved in
chemotherapy induced alopecia.
Secondary outcome
Differences in the dystrophic pathway in patients with and without scalp
cooling.
Background summary
Alopecia is an almost inevitable side effect of chemotherapy treatment. In
cancer patients chemotherapy induced alopecia is experienced as one of the side
effects with de most impact. Several factors may contribute to the severity of
hair loss including dose, drug schedule, combinations with other cytotoxic
agents as well as hair care practices. Research shows scalp cooling is an
effective method to prevent chemotherapy induced hair loss. The exact working
mechanism is unclear. Therefore we do not know why scalp cooling is effective
in one patient but not in another.
Study objective
We will explore the influence of chemotherapy on hair follicles. Scalp cooling
works, but not in every patient. When we understand the working mechanism of
chemotherapy induced alopecia, we can possibly explain why scalp cooling works
in one patient, but not in the other.
Study design
This is a mono-center observational pilot study. The study will be conducted in
the outpatient chemotherapy clinic of the
department of internal medicine of the Medical Center Alkmaar. Patients will be
asked to participate at the time of their first
contact with the oncology nurse to schedule their first chemotherapy. After
providing informed consent, hairs will be
collected during the first chemotherapy course.
Study burden and risks
The burden for patients consists of collecting hairs.
Wilhelminalaan 12
Alkmaar 1815 JD
NL
Wilhelminalaan 12
Alkmaar 1815 JD
NL
Listed location countries
Age
Inclusion criteria
- Patients with cancer
- Indication for at least one cycle docetaxel or paclitaxel
- Age 18 years or more
- Written informed consent
Exclusion criteria
NA
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL59406.094.16 |